EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss of $0.62, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
September 12, 2018 6:00 AM EDT-Substantial progress made in the Companys accelerated transformation into a commercial entity
-YUTIQ PDUFA date of November 5, 2018
-Commercial preparations underway for launch of DEXYCU in the first half of calendar year 2019
-Balance sheet strengthened by $35 million of capital led by EW Healthcare Partners
-Conference call and webcast today, September 12th, at 8:30 AM ET-
WATERTOWN, Mass., Sept. 12, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and... More
